PPARγ antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis

Journal of Neuroimmunology

Volumn 167, Issue 1-2, 2005, Pages 99-107

  Raikwar, Himanshu P ^a   Muthian, Gladson ^a   Rajasingh, Johnson ^a   Johnson, Caroline ^a   Bright, John J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Demyelination; EAE MS; Inflammation; PPAR ; Th1 response

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; ANTIGEN; BENZAMIDE DERIVATIVE; GAMMA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOL DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 2,2-BIS(4-GLYCIDYLOXYPHENYL)PROPANE; EPOXIDE; GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT; PYRIDINE DERIVATIVE; THYMIDINE; TRITIUM;

ALLERGIC ENCEPHALITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; KNOCKOUT MOUSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; WILD TYPE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; COMPARATIVE STUDY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ANIMALS; BENZAMIDES; CELL PROLIFERATION; DEMYELINATING DISEASES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOXY COMPOUNDS; FEMALE; GLYCOPROTEINS; INFLAMMATION; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PPAR GAMMA; PYRIDINES; TH1 CELLS; THYMIDINE; TIME FACTORS; TRITIUM;

EID: 24144471128     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.06.026     Document Type: Article

References (45)

1. Y. Barak, M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, K.R. Chien, A. Koder, and R.M. Evans PPAR gamma is required for placental, cardiac, and adipose tissue development Mol. Cell 4 1999 585 595
2. I.M. Barroso, V.E. Gurnell, M. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, H. Lewis, A.J. Schafer, V.K. Chatterjee, and S. O'Rahilly Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 1999 880 883
3. A. Bitsch, and W. Bruck Differentiation of multiple sclerosis subtypes: implications for treatment CNS Drugs 6 2002 405 418
4. B. Blumberg, and R.M. Evans Orphan nuclear receptors: new ligands and new possibilities Genes Dev. 12 1998 3149 3155
5. J.J. Bright, B.F. Musuro, C. Du, and S. Sriram Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis J. Neuroimmunol. 82 1998 22 30
6. J.J. Bright, M. Rodriguez, and S. Sriram Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced CNS demyelination J. Virol. 3 1999 1637 1639
7. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R.M. Evans PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat. Med. 7 2001 48 52
8. C.Q. Chu, S. Wittmer, and D.K. Dalton Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis J. Exp. Med. 192 2000 123 128
9. M.P. Coleman, and V.H. Perry Axon pathology in neurological disease: a neglected therapeutic target Trends Neurosci. 25 2002 532 537
10. D.J. Cua, J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, S. Zurawski, M. Wiekowski, S.A. Lira, D. Gorman, R.A. Kastelein, and J.D. Sedgwick Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 6924 2003 744 748
11. G. Dean How many people in the world have MS? Neuroepidemiology 13 1994 1 7
12. G.D. Demetri, C.D. Fletcher, E. Mueller, G.D. Demetri, C.D. Fletcher, E. Mueller, P. Sarraf, R. Naujoks, N. Campbell, B.M. Spiegelman, and S. Singer Induction of solid tumor differentiation by the peroxisome proliferator- activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc. Natl. Acad. Sci. U. S. A. 96 1999 3951 3956
13. A. Diab, C. Deng, J.D. Smith, R.Z. Hussain, B. Phanavanh, A.E. Lovett-Racke, P.D. Drew, and M.K. Racke Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis J. Immunol. 168 2002 2508 2515
14. A. Elbrecht, Y. Chen, C.A. Cullinan, N. Hayes, M. Leibowitz, D.E. Moller, and J. Berger Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2 Biochem. Biophys. Res. Commun. 224 1996 431 437
15. E. Elstner, C. Muller, K. Koshizuka, E.A. Williamson, D. Park, H. Asou, P. Shintaku, J.W. Said, D. Heber, and H.P. Koeffler Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc. Natl. Acad. Sci. U. S. A. 95 1998 8806 8811
16. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
17. D.L. Feinstein, E. Galea, V. Gavrilyuk, C.F. Brosnan, C.C. Whitacre, L. Dumitrescu-Ozimek, G.E. Landreth, H.A. Pershadsingh, G. Weinberg, and M.T. Heneka Peroxisome proliferator activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis Ann. Neurol. 51 2002 694 702
18. I.A. Ferber, S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C.G. Fathman Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE) J. Immunol. 156 1996 5 7
19. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B. Spiegelman, and R.M. Evans 15-Deoxy-12,14 prostaglandin J2 a ligand for the adipocyte determination factor PPAR gamma Cell 83 1995 803 812
20. R.J. Franklin Why does remyelination fail in multiple sclerosis? Nat. Rev., Neurosci. 3 2002 705 714
21. R. Gold, H.P. Hartung, and K.V. Toyka Animal models for autoimmune demyelinating disorders of the nervous system Mol. Med. Today 6 2000 88 91
22. B. Hemmer, J.J. Archelos, and H. Hartung New concepts in the immunopathogenesis of multiple sclerosis Nat. Rev., Neurosci. 4 2002 291 301
23. C. Jiang, A.T. Ting, and B. Seed PPARγ agonists inhibit production of monocyte inflammatory cytokine Nature 391 1998 82 86
24. Y. Kawahito, M. Kondo, Y. Tsubouchi, A. Hashiramoto, D. Bishop-Bailey, K. Inoue, M. Kohno, R. Yamada, T. Hla, and H. Sano 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats J. Clin. Invest. 106 2000 189 197
25. S.A. Kliewer, and T.M. Willson The nuclear receptor PPAR-bigger than fat Curr. Opin. Genet. Dev. 8 1998 576 581
26. G. Krey, O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M.G. Parker, and W. Wahli Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Mol. Endocrinol. 11 1997 779 791
27. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ) J. Biol. Chem. 270 1995 12953 12956
28. R. Mukherjee, L. Jow, G.E. Croston, and J.R. Paterniti Identification, characterization and tissue distribution of human peroxisome proliferator activated receptor isoforms 1 and 2 and activation with retinoid × receptor agonists and antagonists J. Biol. Chem. 272 1997 8071 8076
29. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma Cell 93 1998 229 240
30. C. Natarajan, and J.J. Bright Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation Genes Immun. 3 2002 59 70
31. C. Natarajan, G. Muthian, Y. Barak, R.M. Evans, and J.J. Bright Peroxisome proliferator-activated receptor-gamma deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis J. Immunol. 171 2003 5743 5750
32. A. Nencioni, S. Wesselborg, and P. Brossart Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses Crit. Rev. Immunol. 23 2003 1 13
33. B.P. Neve, J.C. Fruchart, and B. Staels Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis Biochem. Pharmacol. 60 2000 1245 1250
34. M. Niino, K. Iwabuchi, S. Kikuchi, M. Ato, T. Morohashi, A. Ogata, K. Tashiro, and K. Onoe Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of PPARγ J. Neuroimmunol. 116 2001 40 48
35. J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis N. Engl. J. Med. 343 2000 938 952
36. T. Owens, and S. Sriram The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis Neurol. Clin. 13 1995 51 73
37. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation Nature 391 1998 79 82
38. S. Schmidt, E. Moric, M. Schmidt, M. Sastre, D.L. Feinstein, and M.T. Heneka Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients J. Leukoc. Biol. 75 2004 478 485
39. S. Schwartz, P. Raskin, V. Fonseca, and J.F. Graveline Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group N. Engl. J. Med. 338 1998 861 866
40. B.M. Spiegelman PPARγ in monocytes-less pain, any gain? Cell 93 1998 153 155
41. L. Steinman, R. Martin, C. Bernard, P. Conlon, and J.R. Oksenberg Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy Annu. Rev. Neurosci. 25 2002 491 505
42. E.H. Tran, E.N. Prince, and T. Owens IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines J. Immunol. 164 2000 2759 2768
43. D.O. Willenborg, S. Fordham, C.C. Bernard, W.B. Cowden, and I.A. Ramshaw IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis J. Immunol. 157 1996 3223 3227
44. T.M. Willson, and W. Wahli Peroxisome proliferator activated receptor agonists Curr. Opin. Chem. Biol. 1 1997 235 241
45. D.M. Wingerchuk, C.F. Lucchinetti, and J.H. Noseworthy Multiple sclerosis: current pathophysiological concepts Lab. Invest. 81 2001 263 281